SOPHiA GENETICS Q1 revenue grows 22% YoY to $21.7M with strong U.S. and global expansion

SOPHiA GENETICS reported a 22% year-over-year revenue increase to $21.7 million in Q1 2026, driven by strong growth in the U.S., Asia Pacific, and EMEA regions. The company performed a record 108,000 genomic analyses and expanded its customer base, including new deals with major hospitals and BioPharma partnerships. Despite an IFRS net loss of $19.3 million, adjusted EBITDA loss improved slightly, reflecting operational efficiencies. SOPHiA GENETICS expects full-year revenue growth of about 20-22% and aims to approach adjusted EBITDA breakeven by the end of 2026.